Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Chenoa Shenandoah

Nurse Practitioner, Psychiatric/Mental Health Knoxville, TN Nurse Practitioner

NPI 1154761542 CMS profile 11084738

318 N Forest Park Blvd, Knoxville, TN 37919

Open in the dashboard

General payments

$9,563

525 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chenoa Shenandoah of Knoxville, TN is reported in the CMS Open Payments database as having received $9,563 across 525 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,878 91
2024 General $1,376 69
2023 General $1,736 100
2022 General $2,031 125
2021 General $2,542 140

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chenoa Shenandoah
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Chenoa Shenandoah were reported at $1,878. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Chenoa Shenandoah Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,542 $166 $54–$482 $132
2022 $2,031 $195 $66–$559 $149
2023 $1,736 $233 $82–$673 $160
2024 $1,376 $236 $84–$688 $164
2025 $1,878 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $1,296 66 payments
  2. Supernus Pharmaceuticals, Inc. $1,084 58 payments
  3. Otsuka America Pharmaceutical, Inc. $954 56 payments
  4. Neurocrine Biosciences, Inc. $825 36 payments
  5. AbbVie, Inc. $787 45 payments
  6. Axsome Therapeutics, Inc. $674 37 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $462 28 payments
  8. Teva Pharmaceuticals USA, Inc. $442 33 payments
  9. Alkermes, Inc. $440 21 payments
  10. Tris Pharma Inc $406 25 payments
  11. Other $2,194 120 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,516 524 payments
  2. Education $47 1 payment
Products named General payments · program years 2021–2025
  1. CAPLYTA $1,063 54 payments
  2. REXULTI $915 54 payments
  3. VRAYLAR $771 44 payments
  4. Auvelity $674 37 payments
  5. QELBREE Psychology $666 41 payments
  6. INGREZZA $664 29 payments
  7. TRINTELLIX $462 28 payments
  8. LYBALVI $425 20 payments
  9. Qelbree Viloxazine Hydrochloride $418 17 payments
  10. FANAPT $406 19 payments
  11. Other $5,019 275 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

56

Median for Nurse Practitioner: 389

Drug cost

$22,428

Median for Nurse Practitioner: $21,885

Branded share of claims

55.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Auvelity Dextromethorphan Hbr/Bupropion Brand 18 $19,901
Quetiapine Fumarate Er Quetiapine Fumarate Brand 13 $2,079
Trazodone Hcl Generic 11 $331
Clonazepam Generic 14 $117

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $310
$310 — —
VRAYLAR
  • AbbVie, Inc. $175
$175 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $151
$151 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $138
$138 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $79
  • Lundbeck LLC $57
$136 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

525 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record